OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

Market Cap	125.29B +26.3%
Revenue (ttm)	87.16B +6.4%
Net Income	11.36B +10.2%
EPS	730.00 +8.1%
Shares Out	17.65M
PE Ratio	9.73
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	181,222
Average Volume	168,533
Open	7,200.00
Previous Close	7,200.00
Day's Range	6,800.00 - 7,200.00
52-Week Range	5,970.00 - 20,750.00
Beta	n/a
RSI	30.20
Earnings Date	Jan 23, 2026

About OPTUS Pharmaceutical

OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company was formerly known as DHP Korea Co., Ltd. OPTUS Pharmaceutical Co., Ltd. was founded in 2002 and is headquartered in Cheongju, South Korea.

• Founded: 2002
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 131030

Financial Performance

In 2025, OPTUS Pharmaceutical's revenue was 87.16 billion, an increase of 6.42% compared to the previous year's 81.90 billion. Earnings were 11.36 billion, an increase of 10.18%.